恩卡尼与普罗帕酮治疗室性心律失常的临床比较研究

Clinical comparative study of encainide and propafenone in chronic ventricular arrhythmias

用单盲安慰剂自身对照法研究43例颁发室早患者口服恩卡尼(En25～50mgq8h)和普罗帕酮(Pro150mgq6h)的疗效。以平均每小时室早减少≥75％或室速完全被抑制为有效。两药的有效率分别为65％与57％．En使PR、QRS、QTc间期各延长26％、29％与7％．比Pro分别延长14％、18％与3％,更显著(P(0．001)。En致心律失常作用的发生率为7％。其与Pro的心外副作用发生率皆为37％,主要是头昏和视觉障碍。

Forty three patients suffering from chronic premature ventricular complexes (more than 60/h ) werc treated orally in a single-blind. placebo-controlled study with encainide (25-50mg every 8 hours, mean 125mg/d ) and propafenone (150mg every 6 hours,600mg/d ). Drug efficacy was assessed by 1. more than 75% reduction in number of premature ventricular conplexes per hour,or 2. absence of ventricular tachycardia. Encainide was effective in 28 patients (65%, 28/43),Propafenone was effective in 20 patients (57%, 20/35). With encainide, the percent increase in PR,QRS and QT. interval duration was,respectively: 26%,29% and 7%. With propafenone, the percent increase was,respectively: 14 %, 18% and 3%.The percent increase of encainide in these interval durations was more than that of propafenone (P <0. 001 ). Encainide and propafenone did not affect on JTc,HR and LVEF,either. The incidence of proarrhythmia was 7% (3/43) in encainide. The incidence of the dide effects (out of heart )was 37% in encainide (16/43) and 37% in propafenone (13/35),they were mainly dizziness and blurred vision